BeiGene, Ltd. (ONC)vsTarsus Pharmaceuticals Inc (TARS)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TARS
Tarsus Pharmaceuticals Inc
$66.96
+6.03%
HEALTHCARE · Cap: $2.69B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1084% more annual revenue ($5.34B vs $451.36M). ONC leads profitability with a 5.4% profit margin vs -14.7%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TARS
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TARS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Revenue surging 128.4% year-over-year
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Trading at 8.3x book value
0.0% earnings growth
ROE of -23.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TARS
The strongest argument for TARS centers on Revenue Growth. Revenue growth of 128.4% demonstrates continued momentum.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TARS
The primary concerns for TARS are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
TARS carries more volatility with a beta of 0.60 — expect wider price swings.
TARS is growing revenue faster at 128.4% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 32/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Tarsus Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?